Data protection Impressum

Financing

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (February 2024)

27 February 2024

This latest funding round, combining equity, debt financing, and a non-dilutive grant, marks a significant milestone in MeduSoil’s journey towards promoting sustainable construction practices.

MeduSoil secures fresh funding to propel sustainable construction forward

12 February 2024

The vision of the Sitem Startup Club is clear: to establish Bern as the leading hub for medtech start-ups in Switzerland and beyond.

Sitem Startup Club, where medtech start-ups thrive in Bern

Transmutex’s funding milestone marks a significant step towards realizing safer, more sustainable nuclear energy solutions, potentially transforming the global energy landscape.

Transmutex receives CHF 20 million for its breakthrough nuclear energy technology

5 February 2024

GeNeuro‘s mission is to leverage HERV biology to develop safe and effective treatments for the benefit of patients, by neutralizing causal factors encoded by HERVs that represent 8% of human DNA.

GeNeuro secures EUR 5 million to advance post-COVID and neurodegenerative disease treatments

5 February 2024

In 2023, Swiss start-ups faced a challenging investment climate, marked by a significant reduction in venture capital funding.

Business environment

Swiss start-ups raised CHF 2.6 billion in 2023

30 January 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (January 2024)

30 January 2024

Timeline’s new funding round, led by BOLD (Business Opportunities for L’Oréal Development), includes strategic investments from industry giants L’Oréal and Nestlé.

Timeline secures CHF 56 million to propel its pioneering role in longevity and healthy aging

24 January 2024

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers.

Cellestia Biotech receives CHF 2 million for its pioneering GvHD prevention therapy

23 January 2024

STALICLA has developed the first neurodevelopmental disorder-specific precision medicine platform with an initial application in autism spectrum disorder (ASD).

STALICLA secures USD 17.4 million to propel neuro precision medicine

22 January 2024

1 … 17 18 19 20 21 22 23 24 25 … 38